Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Trial-Reference-Cited by-同舟云学术

Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Trial

Published:2009-05 Issue:5 Volume:55 Page:1112-1123
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

James Nicholas D.,Caty Armelle,Borre Michael,Zonnenberg Bernard A.,Beuzeboc Philippe,Morris Thomas,Phung De,Dawson Nancy A.

Publisher

Elsevier BV

Subject

Urology

Reference30 articles.

1. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world;Kamangar;J Clin Oncol,2006

2. Mechanisms leading to the development of hormone-resistant prostate cancer;Kasper;Urol Clin North Am,2006

3. Bisphosphonates to prevent skeletal complications in men with metastatic prostate cancer;Smith;J Urol,2003

4. Current indications for chemotherapy in prostate cancer patients;Calabrò;Eur Urol,2007

5. EAU guidelines on prostate cancer;Heidenreich;Eur Urol,2008

Cited by 137 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current and future strategies for targeting the endothelin pathway in cardiovascular disease;Nature Cardiovascular Research;2023-11-02

2. Gene Therapy and Cardiovascular Diseases;Advances in Experimental Medicine and Biology;2022-12-02

3. Targeting signaling pathways in prostate cancer: mechanisms and clinical trials;Signal Transduction and Targeted Therapy;2022-06-24

4. Zibotentan in systemic sclerosis-associated chronic kidney disease: a phase II randomised placebo-controlled trial;Arthritis Research & Therapy;2022-06-01

5. Systemic Management for Nonmetastatic Castration-resistant Prostate Cancer;American Journal of Clinical Oncology;2020-01-17